Skip to main content

Table 3 Univariate analysis of survival at day 28 for baseline covariates significantly different between the angiotensin II dose groups

From: Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial

  Patients, n,  % (95% CI) Hazard ratio* (95% CI) P value
Angiotensin II > 5 ng kg−1 min−1 Angiotensin II ≤ 5 ng kg−1 min−1
Baseline MAP
 ≥ 65 mmHg 47, 44.7 (30.2–58.1) 64, 67.2 (54.2–77.2) 0.52 (0.29–0.92) 0.023
 < 65 mmHg 37, 37.4 (22.1–52.7) 15, 66.7 (37.5–84.6) 0.38 (0.14–1.00) 0.041
Baseline norepinephrine-equivalent dose
 < 0.5 µg kg−1 min−1 50, 47.4 (33.0–60.5) 67, 68.7 (56.1–78.3) 0.53 (0.30–0.95) 0.030
 ≥ 0.5 µg kg−1 min−1 34, 32.4 (17.6–48.0) 12, 58.3 (27.0–80.1) 0.45 (0.17–1.19) 0.100
Baseline angiotensin I
 < 72.3 pg/mL 12, 41.7 (15.2–66.5) 24, 66.7 (44.3–81.7) 0.49 (0.18–1.35) 0.160
 72.3 to < 253 pg/mL 14, 42.9 (17.7–66.0) 19, 57.9 (33.2–76.3) 0.56 (0.21–1.48) 0.234
 253 to < 676 pg/mL 25, 39.3 (20.5–57.6) 14, 85.7 (53.9–96.2) 0.18 (0.04–0.80) 0.011
 ≥ 676 pg/mL 23, 52.2 (30.5–70.0) 14, 50.0 (22.9–72.2) 1.02 (0.40–2.64) 0.962
Baseline angiotensin II
 < 23.85 pg/mL 14, 28.6 (8.8–52.4) 21, 71.4 (47.2–86.0) 0.29 (0.10–0.80) 0.011
 23.85 to < 83.75 pg/mL 11, 36.4 (11.2–62.7) 21, 71.4 (47.2–86.0) 0.37 (0.12–1.09) 0.060
 83.75 to < 299.5 pg/mL 25, 43.2 (23.5–61.5) 21, 57.1 (33.8–74.9) 0.64 (0.27–1.47) 0.285
 ≥ 299.5 pg/mL 24, 58.3 (36.4–75.0) 7, 57.1 (17.2–83.7) 1.01 (0.28–3.66) 0.993
  1. CI, confidence interval; MAP, mean arterial pressure
  2. *Hazard ratio/log-rank test result of treatment effect within subgroup